ARCHIVES

DCT’s Experimental Therapeutic Program Outlined to Board

This article is from The Cancer Letter archive.

Vol. 01 No. 18 | May 2, 1975

Download PDF Visit The Full Archive

Related Articles

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

May 6, 2005

In Brief: No More Shifts Planned For Treatment Programs; Groups Seek Surgeon, Radiologist Incentives

August 29, 1975

NCI Awards Regional CIS Contracts

August 6, 1993

Texas Cancer Plan Features Big Hike in Cigarette Tax

September 19, 1986

FA Drug Approval on Activity, Rather Than Survival Urged By NCU

January 13, 1989

Program Project Guidelines Available

October 27, 1995